Skip to main content
MSF.org
  • English
  • العربية
  • Español
  • Français
MSF medical guidelines
MSF medical guidelines

Main navigation

  • Home
  • Guidelines
  • Updates
  • Order
  • About
  • Favorites
  • Contact

All guidelines

Tuberculosis

Essential drugs

English العربية Spanish French

Clinical guidelines - Diagnosis and treatment manual

English العربية Spanish French

Essential obstetric and newborn care

English العربية French

Management of A CHOLERA EPIDEMIC

English French

Management of A MEASLES EPIDEMIC

English French

Tuberculosis

English French

Public health engineering

English French
  • Authors/Contributors
  • Introduction
  • Abbreviations and acronyms
  • Chapter 1: Introduction and epidemiology
  • Chapter 2: Clinical presentation
  • Chapter 3: Diagnostic investigations
  • Chapter 4: Diagnostic algorithms for pulmonary tuberculosis (PTB) in adults and adolescents
  • Chapter 5: Diagnosis of tuberculosis in children
  • Chapter 6: Intensive case finding in HIV-infected individuals
  • Chapter 7: Case definitions for registration
  • Chapter 8: Anti-TB drugs and treatment regimens
  • Chapter 9: Treatment of drug-susceptible tuberculosis
  • Chapter 10: Treatment of multidrug-resistant TB (MDR-TB)
    • 10.1 Design of therapeutic regimens in MDR-TB
    • 10.2 Selection of anti-TB drugs in MDR-TB regimens
    • 10.3 Building a treatment regimen for MDR-TB
    • 10.4 Duration of MDR-TB regimens
    • 10.5 Follow-up for patients treated for MDR-TB
    • 10.6 Management of adverse effects in patients on second-line regimens
    • 10.7 Surgery as an adjunctive treatment measure
    • 10.8 Management of patients whose treatment failed and palliative care
    • 10.9 Special situations
    • 10.10 Treatment of extensively drug-resistant TB (XDR-TB)
  • Chapter 11: Treatment of mono- and poly-drug resistant tuberculosis (PDR-TB)
  • Chapter 12: Co-management and treatment of HIV in TB disease
  • Chapter 13: Adherence to tuberculosis treatment
  • Chapter 14: Tuberculosis infection control
  • Chapter 15: Follow-up of staff exposed to tuberculosis
  • Chapter 16: Treatment of latent tuberculosis infection
  • Chapter 17: Monitoring and evaluation
  • Appendices

Breadcrumb

  • Home
  • Tuberculosis

Chapter 10: Treatment of multidrug-resistant TB (MDR-TB)

Select language:
Enter
Download
Comment
Return to top
On this page

     

     

    • 10.1 Design of therapeutic regimens in MDR-TB
    • 10.2 Selection of anti-TB drugs in MDR-TB regimens
    • 10.3 Building a treatment regimen for MDR-TB
    • 10.4 Duration of MDR-TB regimens
    • 10.5 Follow-up for patients treated for MDR-TB
    • 10.6 Management of adverse effects in patients on second-line regimens
    • 10.7 Surgery as an adjunctive treatment measure
    • 10.8 Management of patients whose treatment failed and palliative care
    • 10.9 Special situations
    • 10.10 Treatment of extensively drug-resistant TB (XDR-TB)

     

    Path

    Book traversal links for Chapter 10: Treatment of multidrug-resistant TB (MDR-TB)

    • 9.6 Management of treatment interruption in patients on first-line regimens
    • 10.1 Design of therapeutic regimens in MDR-TB

    Send feedback about this page or ask a general question

    MSF medical guidelines
    MSF medical guidelines
    © Médecins Sans Frontières 2022

    Footer

    • Disclaimer
    • Cookie Policy
    • Privacy Notice